BPC-157 Dosing & Protocols — Research Reference

BPC-157 (Body Protection Compound 157) is a pentadecapeptide fragment widely studied in tissue-repair, gastrointestinal, and vascular research. This guide compiles dosing references, reconstitution practice, and scheduling patterns most commonly cited in published preclinical and translational research.

Reconstitution for Research

BPC-157 is typically supplied as a lyophilized powder. Standard research practice reconstitutes 5 mg with 2–5 mL bacteriostatic water (BAC), yielding concentrations of 1–2.5 mg/mL. The reconstituted solution is stable refrigerated for 30+ days based on stability data on the COA. Always confirm batch-specific stability with the supplier's certificate of analysis.

Reference Dose Ranges in Published Research

| Research model tier | Typical range | Notes | |---|---|---| | Low-dose / general systemic | 200–300 mcg/day | Most-cited entry dose for systemic GI and recovery research models | | Standard tissue-repair | 250–500 mcg/day | Most-frequently cited tier across tendon, ligament, and muscle research | | High-dose research | 500–1000 mcg/day, split BID | Acute injury models or models requiring localized concentration |

Scheduling

Subcutaneous injection is the most-cited research route, often delivered as close to the target tissue as practical for localized models. Published timing patterns typically use once-daily dosing for systemic endpoints and twice-daily (AM/PM, split) dosing for acute tissue-repair models. Oral administration has been investigated and shows activity in GI models specifically, though systemic bioavailability is limited.

Cycling in the Published Literature

The most-cited cycling pattern in research is 4 weeks on / 2 weeks off, though continuous-administration studies extending 8–12 weeks have been published without significant tolerance development. Researchers studying GI mucosal repair commonly use shorter 2–4 week protocols matched to model endpoints.

Common Research Endpoint Markers

Common research endpoints include collagen synthesis markers, VEGFR2 expression, nitric oxide pathway activation, and tissue tensile-strength measurements. GI research commonly tracks mucosal histology and stool/inflammatory markers.

Common Research Pairings

Most-cited pairing is BPC-157 + [TB-500](/research/hubs/tb-500) for complementary tissue-repair mechanisms (cytoprotection + cell migration). Recovery research models also pair BPC-157 with [GHK-Cu](/research/hubs/ghk-cu) for matrix remodeling endpoints.

Storage & Stability

Lyophilized BPC-157 is stable at room temperature for short periods but should be stored long-term at 2–8 °C protected from light. Reconstituted solution stores refrigerated; freeze-thaw cycles should be minimized.

Frequently Asked Questions

Does BPC-157 require subcutaneous administration?

Subcutaneous is the dominant route in research, but oral has been validated specifically for GI mucosal endpoints. Intramuscular near a target tissue is used in some musculoskeletal models.

What's the difference between BPC-157 arginate and acetate salts?

The acetate salt is the most-cited research form. Arginate has been promoted for stability but the published mechanistic literature is dominated by the acetate. Always confirm salt form on the COA.

How long do research effects persist after cessation?

Tissue-level effects (collagen deposition, vascular changes) persist beyond the short plasma half-life because the structural changes accumulate. Most research observes endpoint persistence for weeks after cessation.

Research-Use Disclosure

All content is provided strictly for laboratory research purposes. Compounds discussed are research chemicals and are not for human or veterinary consumption. Dosing ranges referenced below are summaries of published preclinical and clinical research literature compiled for laboratory reference only — they are not medical recommendations.